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Abstract The practice and development of modern medicine requires large
amounts of data, particularly in the domain of cancer. The future of personalized
medicine lies neither with ‘‘genomic medicine’’ nor with ‘‘precision medicine’’, but
with ‘‘data medicine’’ (DM) (big data, data mining). The establishment of this DM
has required far-reaching changes, to establish four essential elements connecting
patients and doctors: biobanks, databases, bioinformatic platforms and genomic
platforms. The ‘‘transformation’’ of scientific research areas, such as genetics,
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bioinformatics and biostatistics, into clinical specialties has generated a new vision
of care. Molecular tumor boards (MTB) are one response to these changes and are
now providing better access to next-generation sequencing (NGS) and new cancer
treatments to patients with inoperable or metastatic cancers, and those for whom the
usual treatment has failed. However, MTB face a crucial ethical challenge: main-
taining and improving the trust of patients, clinicians, researchers and industry in
academic medical centers supported by private or public funding rather than pro-
viding genetic data directly to private companies. We believe that, in this era of
DM, appropriate modern digital communication networks will be required to
maintain this trust and to improve the organization and effectiveness of the system.
There is, therefore, a need to reconsider the form and content of informed consent
(IC) documents at all academic medical centers and to introduce dynamic and
electronic informed consent (e-IC).
Keywords Personalized medicine  Data medicine (DM)  Molecular tumor board
(MTB)  Electronic informed consent (e-IC)  Dynamic consent  Biobank 
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Introduction
In 1950, the American mathematician Norbert Wiener proposed that ‘‘Society can
only be understood through a study of the messages and the communication
facilities which belong to it’’ (Weiner 1950). Extrapolating this idea to medicine, we
can see that the communications facilities used are increasingly electronic and that
the messages transmitted contain ever-larger amounts of genetic data from patients
for use in care or research. Medicine now requires large amounts of data to function
and develop, particularly in the domain of cancer. This is why, in our opinion,
personalized medicine should not be called ‘‘genomic medicine’’ or ‘‘precision
medicine’’, but ‘‘data medicine’’ (DM) (although this term is currently rarely used in
the scientific literature).
Indeed, advances in computer science and technology are leading to new clinical
tools and methods (specific algorithms) for deducing suspected clinical information
(e.g. targeted mutations approved) from a large amount of raw data, including
genetic data in particular. This data-mining approach (Delort 2015) would appear at
first glance to fit into a context of ‘‘genomic medicine’’ or ‘‘precision medicine’’.
However, some of these new tools and methods (e.g. machine or deep learning) are
making it possible to induce unsuspected clinical information (e.g. new mutation or
validation of a targeted mutation non-approved) from a large amount of raw data
(possibly even larger amounts of even more preliminary data). The big data
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approach (Delort 2015). DM can therefore be seen as more complex than genomic
or precision medicine and encompassing both the ‘‘old’’ data mining approach and
the ‘‘new’’ big data approach. This is a particularly important point that needs to be
taken on board by all.
In this new framework, DM has required the establishment of a set of four
essential elements connecting patients and clinicians (Fig. 1): (1) biobanks for the
storage of biological samples; (2) genomics platforms, for generating genetic data
from biological samples; (3) databases, for the storage of genetic data; (4)
bioinformatics platforms, for the production of clinical information from genetic
data (and other raw data). The ‘‘transformation’’ of scientific research areas, such as
genetics, bioinformatics and biostatistics, into clinical specialties has led to the
emergence of a new vision of care, mostly due to demonstrated clinical benefits of
DM and the significant and rapid decrease in the price of new technologies.
At most academic medical centers, the meetings at which cancer diagnosis and
treatment are discussed, known as tumor boards (TB) are open only to oncologists,
surgeons, pathologists and radiologists (Kuroki et al. 2010). However, some patients
have inoperable tumors and others suffer treatment failure after surgery. This has
led to the emergence of a new type of structure, molecular tumor boards (MTB), in
which surgeons are replaced by geneticists, bioinformaticians and biostatisticians
(Schwaederle et al. 2014). These structures are endowed with a new mixture of
skills, to meet new challenges in cancer care and treatment.
MTB are providing better access to next-generation sequencing (NGS) and new
cancer treatments to patients with inoperable or metastatic tumors, and patients for
whom the usual treatment has failed, increasing the chances of these patients living
longer or even avoiding a fatal outcome of their disease (Erdmann 2015). Before the
creation of MTB, translational research was established to provide researchers and
industry with better access to patients, biological samples and genetic data via
Fig. 1 Model of the data medicine process. Biological sample flows and biobanks are shown in green.
Data flows and databases are shown in light blue. Information flows are shown in dark blue
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academic medical centers. Some MTB are thus located at centers of translational
research (Kamal et al. 2015).
The equivalence of public and private structures is complex, and a first, key
question concerns the status of the genetic data generated. Are they genetic data for
care, for research, or for both at the same time? This question may seem trivial, but
the answer is crucial, for both patient autonomy and for the chain of trust connecting
patients, clinicians, researchers and industry in real time, at academic medical
centers, in the new era of DM. Clinical trials and retrospective studies are
increasingly frequent in this new era, but they remain poorly understood by patients
(Jefford and Moore 2008).
This lack of understanding is behind one of the most important ‘‘ethical
challenges’’ confronting MTB: finding ways to maintain and improve the trust of
patients, clinicians, researchers and industrials in academic medical centers in the
era of DM. Based on Weiner’s ideas, we believe that modern and appropriate
facilities (electronic and dynamic) for communication between the varies parties
and clear messages (purpose of care or research) will be required to achieve this
goal. (Annas 2001; Dixon et al. 2014; Kaye et al. 2015; Williams et al. 2015;
Spencer et al. 2016; Steinsbekk et al. 2013). We think that the form and content of
informed consent (IC) documents should be reconsidered, in the Internet age, when
next-generation sequencing may be carried out for any patient in a research protocol
or receiving care.
We think that patients would benefit from greater honesty, and transparency, but
also from modern approaches and real-time interactions concerning the use of their
biological samples and genetic data, to encourage them to continue going to
academic medical centers rather than providing genetic data directly to private
companies, as has been observed in the recent past (Stoekle et al. 2016). Several
new private companies specializing in genomics or informatics have recently been
set up in the US and are establishing strong communication networks in real time,
directly between patients and the pharmaceutical industry (two-sided market) via
Internet and cloud computing, without the involvement of academic medical centers
(Stoekle et al. 2016). These new issues are particularly important in countries in
which social insurance systems are mostly based on solidarity (social security)
rather than individual ability to pay. Patients may thus, one day, have free access to
their own genetic information, which they will be able to use as they see fit.
A global view is essential, to determine how MTB can establish a win–win
strategy with patients that goes beyond current patient-physician relationships. We
discuss here the social, scientific, economic and ethical issues raised by new
dynamic and interactive relationships between patients, clinicians, researchers and
industry that could serve as the basis of DM at an academic medical center.
The Molecular Tumor Board Model
Tumor boards (TB) (or ‘‘multidisciplinary teams’’ (MDT) in the UK, Common-
wealth and Switzerland) have long been a feature in scientific studies (Gross 1987;
Wright et al. 2007; Coory et al. 2008; Fleissig et al. 2006). According to the
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National Institutes of Health (NIH) in the US, TBs are ‘‘a treatment planning
approach in which a number of doctors who are experts in different specialties
(disciplines) review and discuss the medical condition and treatment options of
patient’’. Three different specialties are, therefore, generally represented: a medical
oncologist, a surgical oncologist and a radiation oncologist [NIH website (www.
cancer.gov)]. The TB may also include a pathologist, although this possibility is not
discussed by the NIH (Fig. 2a) (Kuroki et al. 2010).
The primary objective of TB is to improve diagnosis and treatment selection,
thereby improving care management for the patient (Fig. 2a) (Keating et al. 2013).
However, TB were also designed to improve communication and interactions
between the different specialties (e.g. pathology and imaging platforms) (Ruhstaller
et al. 2006). However, the specialties represented on the TB are essentially clinical.
There are no scientists among TB members and little communication occurs
between clinicians and scientists (Gross 1987; Wright et al. 2007; Coory et al. 2008;
Fleissig et al. 2006; Keating et al. 2013; Ruhstaller et al. 2006). This absence of
scientists may reflect the predominance of histological, tissue- or organ-based
approaches. In such conditions, scientific expertise from a genomics or bioinfor-
matics platform is not required for diagnosis (radiology, immunochemistry) or for
the selection of the ‘‘usual’’ types of treatment (surgery, chemotherapy, radiother-
apy) (Fig. 2a).
In parallel, scientists have been involved in clinical research, creating new cancer
treatments (targeted therapies), such as Herceptin (trastuzumab) and Avastin
(bevacizumab), which were developed by the American biotechnology company
Genentech, Inc. (Roche) and have been on sale since the 1990s. Formally, TB were
not designed to provide patients with support after surgery, but some patients have
Fig. 2 a The tumor board model, versus b the molecular tumor board model
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inoperable tumors or suffer treatment failure after surgery; others have metastatic
tumors or suffer treatment failure on usual treatments (Erdmann 2015). The advent
of these targeted therapies has, thus, opened up new possible roles for scientists in
the domain of treatment, particularly for patients with otherwise unresponsive
tumors (Santa-Maria and Gradishar 2015). Since the advent of targeted therapy,
cancer can be seen not only as the consequence of an organ dysfunction, but also as
a molecular abnormality due to a specific genetic alteration that must be identified
by molecular tests, such as DNA sequencing, in particular.
The choice of name—‘‘molecular tumor board’’ (MTB)—perfectly reflects this
‘‘scientization’’ of medicine (Vanneman and Dranoff 2012; Sawyers 2004; Rouviere
et al. 2015; Huang et al. 2014; Dausset 1996). For the moment, very few scientific
papers have referred to a MTB. Only the University of California San Diego
(UCSD) Moores Cancer Center (US) (Schwaederle et al. 2014), the Cleveland
Clinic (US) (Sohal et al. 2016) and the Curie Institute (France) (Kamal et al. 2015)
seem to have already published research articles or reviews about a MTB or similar
structures with a different name. Indeed, as for TB, MTB may also be given other
names, such as ‘‘molecular biology boards’’ (Curie Institute) or ‘‘genomics tumor
boards’’ (Cleveland Clinic). An article published in Nature Medicine in July 2015
estimated that there were 30 MTB across the US (Erdmann 2015).
In France, MTB are called re´union de concertation pluridisciplinaire mole´cu-
laire (molecular multidisciplinary meetings). They have been developed at the
Curie Institute (Kamal et al. 2015), the Gustave Roussy Institute (Gillet 2010) and
the Assistance Publique des Hoˆpitaux de Paris (the Parisian hospital network),
including, in particular, Hoˆpital Europe´en Georges Pompidou (Georges Pompidou
European Hospital) and Hoˆpital Tenon (Tenon Hospital) (Rouviere et al. 2015).
Other such structures are likely to develop throughout France in the near future, in
response to new health and research policies concerning cancer diagnosis and
treatment.
Regardless of differences in the names of these structures between countries,
their organization and function appear to be similar in the US and France: a group of
oncologists, radiologists, pathologists, biologists, geneticists, bioinformaticians,
biostatisticians, researchers and clinicians providing patients presenting treatment
failure with access to NGS diagnostic techniques (genomics and bioinformatics
platforms) and new cancer treatments (targeted therapies), mostly through inclusion
in clinical trials. Surgery has been replaced in these structures by domains of
scientific research, such as genetics, bioinformatics and biostatistics (Fig. 2b),
which are developing into new medical specialties, due to demonstrated clinical
benefits and a rapid and significant fall in the cost of new technologies, such as
NGS.
For 30 years, all DNA sequencing was carried out by the Sanger method
(Schuster 2008). NGS devices first appeared in 2007 and owe their success to
synchronous sequence analysis, resulting in faster, more sensitive analyses, at a
lower overall cost (Meldrum et al. 2011). Indeed, whereas Sanger’s direct (or first-
generation) sequencing method requires the generation of DNA strands of different
lengths labeled with a fluorophore for analysis, NGS methods reconstruct previously
prepared DNA strands by directly determining the nucleic acids incorporated
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(Shendure and Ji 2008). NGS costs have decreased markedly, and this method is
now being transferred from purely research uses to clinical applications. Diagnostic
NGS (RNA, gene panels and whole-exome sequencing) is specific to MTB and
helps to provide patients with access to targeted therapy (Erdmann 2015). There are
currently moves in France to provide full social security reimbursement for patients
undergoing NGS tests.
According to the NIH website (NIH website (www.cancer.gov)), targeted therapy
(also known as ‘‘molecularly targeted drugs’’, ‘‘molecularly targeted therapy’’, or
‘‘precision medicine’’) is more qualitative in its action, whereas chemotherapy is
more quantitative: targeted therapy acts on specific molecular targets in tumor cells,
whereas chemotherapy acts on all rapidly dividing cells (normal and cancerous);
targeted therapies often block tumor cell proliferation (cytostatic), whereas
chemotherapy kills tumor cells (cytotoxic). The available targeted therapies include
hormone therapy, signal transduction inhibitors, gene expression modulators,
apoptosis inducers, angiogenesis inhibitors, immunotherapies and toxin delivery
molecules (Sawyers 2004; Huang et al. 2014).
The FDA has approved some of these therapies, which have clearly proved
effective against certain types of cancer (Herceptin in breast cancer), but most are
still at the clinical trial stage. This is not particularly surprising, because these
treatments are in their infancy, and some have been approved for the treatment of
one type of cancer but may be useful against others and, therefore, require further
trials to gain approval for an expansion of their indications. Most of the patients
undergoing sequencing do not receive targeted treatment, even in trials. According
to a USCD study, ‘‘the most common reasons for being unable to act on molecular
diagnostic results were that patients were ineligible for or could not take part in an
appropriately targeted trial and/or that insurance would not cover the cognate
agents’’ (Schwaederle et al. 2014). A similar observation was made at the Cleveland
Clinic, where a study revealed that only 24 of the 250 patients with selected solid
tumors received targeted therapy, mostly due to a lack of clinical access to treatment
or a deterioration of the patient’s clinical condition (Sohal et al. 2016).
Ethical Issues
According the previous publications, independently of their clinical functions
(which form the focus of most studies), MTB are also starting to coordinate the flow
of biological samples, genetic data and information between patients and clinicians,
but also between researchers at academic medical centers and industry, through
clinical trials and retrospective studies (Fig. 3). If the intensity of these flows
continues to increase, then, in the future, MTB or similar structures may play a
much greater role in deciding who has access to these data. Thus, the MTB or
similar structures may become major decision-makers at academic medical centers,
facilitating the transfer of data from care to research contexts.
This would also improve the tracing of important decision-making processes, and
their organization around a group of field experts in DM. In this era of major
revolutions in science and technology (big data, data mining, machine learning,
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artificial intelligence, cloud computing, etc.), it has been suggested that the experts
involved in these decision-making processes will no longer be exclusively medical
doctors. Instead, these groups of experts will include scientists, statisticians and
informaticians. These changes are likely to have a strong impact, and they raise
several ethical issues, some of which are already of importance, including the
reasons for communicating with patients and how best to do so, particularly as
concerns the biobanks, databases, genomic or bioinformatic processes, clinical trials
and retrospective studies developed through these flows. They also add to the risk of
unequal access to these technologies on the basis of socioeconomic or genetic
criteria.
Many clinical trials may be considered as treatment options because they provide
some patients with a ‘‘last chance’’ of recovery. Nevertheless, clinical care and
clinical research differ in that the objective of care is to be of benefit to a patient,
whereas the objective of research is to gain new knowledge (Jefford and Moore
2008). The information provided to the patient when consent is sought also differs
considerably between clinical care and research: for research, the information and
the goals are explained in the conditional tense, because there are far fewer
certainties than for clinical care. Indeed, one of the first objectives of clinical trials is
to determine whether the new treatment works better than the old one. Furthermore,
the new treatment may entail unknown or theoretical risks, which is less likely to be
the case for a treatment that is already authorized. Thus, the first ethical issue raised
by a MTB is the following: if a treatment is prescribed on inclusion in a clinical
trial, can it still be considered to be clinical care?
This is a particularly important issue, given that scientific studies of a MTB have
reported essentially inclusions in clinical trials rather than the prescription of
Fig. 3 Model of the molecular tumor board process. Biological sample flows and biobanks are shown in
green. Data flows and databases are shown in light blue. Information flows are shown in dark blue
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authorized cancer treatments (Le Tourneau et al. 2012; Kamal et al. 2015; Sohal
et al. 2016; Schwaederle et al. 2014). Furthermore, there are several different levels
of clinical trials. For example, phase I clinical trials are designed to assess the
toxicity of a new treatment in human subjects (acceptable dose levels) and are often
conducted on patients presenting treatment failure (Brown et al. 2011). Therapeutic
benefits are more likely to be seen in phase II and III trials, which test therapeutic
efficacy rather than toxicity. However, the issue is more complex for targeted cancer
therapy, and several studies have reported direct therapeutic benefit in phase I trials
(Khan et al. 2016), even though the patient’s clinical condition (Sohal et al. 2016)
and the quality or quantity of biopsy material can be a barrier to participation in
such clinical trials (Lim et al. 2016).
For these reasons, ‘‘possible care’’, ‘‘conditional care’’ or ‘‘potential care’’ should
be considered, rather than just ‘‘care’’, and these concepts should be explained in
more detail to patients to ensure that they understand the consent form they are
asked to sign. These adjectives qualifying ‘‘care’’ are therefore of great importance,
because a short-term individual benefit is for the moment, merely possible; in
theory, trials are seeking to obtain long-term collective benefit. But can this ‘‘care
modify the ‘‘theory’’? Perhaps, and it might even be a good thing if it did, because
the frequent inclusion of cancer patients in clinical trials necessitates a new strategy
for communication between patients, clinicians, researchers and industry. We need
to make use of ethical discussions about the content and form of IC, to find new
ways of improving the patients’ understanding of their participation in clinical trials
(Kelley et al. 2015; Kao et al. 2016) (Fig. 3).
The publication of the first draft sequence of the human genome (Lander et al.
2001; Venter et al. 2001), and its completion by the Human Genome Project marked
an increase in the strategic importance of DNA banking and data collection. In the
past, biological samples were stored in a single laboratory, but large collections of
DNA samples are becoming increasingly common in human genetics (Thornton
et al. 2005). DNA can be obtained from a number of potential sources, including the
blood, the cell and tissue banks of hospitals and academic research centers, and it
has been estimated that there are already several hundred million biological samples
stored in such repositories (Swede et al. 2007).
Biobanks are becoming increasingly important for the establishment of research
infrastructures (Castillo-Pelayo et al. 2015), and the systematization of NGS,
clinical trials and retrospective studies in cancer may render these repositories of
even greater importance, through a cyclic phenomenon. As more clinical trials are
set up and more patients have their DNA sequenced, there will be more biological
samples, genetic data and clinical information stored in biobanks, leading to more
retrospective studies being carried out and more clinical trials being designed.
Retrospective studies could play a key role in completing the loop. However,
researchers cannot know in advance which topics they will address through
retrospective research studies. It is not, therefore, possible to provide patients with
‘‘perfect information’’, that is to say, a description of all possible research purposes
in advance, when they sign an informed consent form. Institutional review boards
and ethics committees generally require consent to disclose all of the ways in which
samples and data may be used and to ensure an acceptable balance between risks
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and benefits (Godard et al. 2003; Rothstein 2002). This is why some recent studies
have tried to determine whether patients prefer a ‘‘re-consent’’ or a ‘‘broad-consent’’
process, but no clear consensus has yet to emerge (Edwards et al. 2016; Goodman
et al. 2016).
The increasing number of retrospective studies being carried out on cancer, using
data collected in clinical studies, requires a new strategy for communication
between patients, clinicians, researchers and industry, and ethical reflections are
required about the content and nature of the informed consent collected, with the
possibility of returning to patients if necessary (Edwards et al. 2016). This approach
should improve the patients’ understanding of research protocols, increasing their
autonomy and their trust in academic medical centers (Fig. 3). However, it will
require a particularly well-adapted form of informed consent.
Informed consent is much more than a simple form of communication between
patients, clinicians, researchers and industry (Annas 2001). With the increasing
numbers of retrospective studies based on data from clinical trials in the field of
cancer, we need to consider the form of informed consent given, and not just its
content, at all academic medical centers at which there are close ties between care
and research. Recent innovations in information technology (IT) could drive
changes in strategy concerning communication between patients, clinicians,
researchers and industry (Kaye et al. 2015).
Trust is based primarily on communication. If patients feel that they can
communicate freely, anywhere, at any time and in complete safety, they are more
likely to trust the system and to be willing to share their data and biological samples.
An electronic informed consent (e-IC), or dynamic consent (Kaye et al. 2015;
Steinsbekk et al. 2013; Dixon et al. 2014; Williams et al. 2015; Spencer et al. 2016)
system would open up new possibilities: (1) for patients to determine whether or not
to give consent, at the time and place of their choosing, (2) for clinicians to ensure,
in real time, that a particular piece of information has been transmitted to a
particular patient and to determine whether or not the patient concerned has given
consent and (3) for researchers and industry, to facilitate the use, in real time, of
particular samples or data (Karlson et al. 2016).
The FDA [according to a draft document available from the FDA website (www.
fda.gov)] has identified IT as a good way of improving communication between
patients and clinicians through multiple media: text, graphics, audio, video, podcasts
and interactive websites, biological recognition devices and reader cards to relay
information about the study and to obtain informed consent. The FDA draft dis-
cusses the possibility of e-IC. Nevertheless, the FDA draft stresses that the content
requirements for e-IC should be identical to those for written informed consent: the
information should describe and explain clearly the purpose of the study or analysis
and it should be easy for the patient to understand the aim of the research.
In general, e-IC facilitates more interactive and dynamic exchanges of
information and improves the traceability of biological samples, genetic data and
information (Kaye et al. 2015). This process has already been well understood by a
number of companies in the US, including Google, Amazon, Facebook, Apple
(GAFA), Microsoft, 23andMe, and Helix, a new company that will soon begin
trading.
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A global view is required to visualize how the rapid sharp decrease in the cost of
DNA sequencing and cloud computing has initiated a flow of biological samples
and genetic data directly between patients, researchers and industry, leaving some
academic medical centers excluded (Fig. 4).
The situation on the ground has changed radically since the 1990s, and several
American companies specializing in genomics or informatics appear to have
established two-sided market (TSM) platforms through the constitution of biobanks
or databases with two kinds of customers: individuals seeking information about
their own genes, with or without the need for a prescription from their physicians,
and industrial and researcher clients seeking access to the genetic, web behavior and
self-reported data obtained from large numbers of people through a commercial
contract involving dynamic, electronic informed consent.
23andMe is probably the best known of these companies. Since 2006, this genetic
testing company has collected biological samples, genetic data and information
from 1,000,000 individuals, at least officially through a direct-to-consumer (DTC)
online genetic testing service providing a genetic ancestry report and a genetic
health report. In reality, the primary objective of the company was not the provision
of DTC testing services, but the establishment of a TSM: promoting itself as
providing predictive testing for human genetic diseases and ancestry at a low cost to
consumers, whilst establishing a high-value database/biobank for research and
industry, for scientific and financial gain (Stoekle et al. 2016). The commercial
agreements between 23andMe and Genentech for Parkinson’s disease provide
strong evidence of the commercialization of the company’s biobank and database
(Mullard 2015).
Fig. 4 Model of the two-sided market process. New biological sample, data and information flows are
shown in red
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A new company of the same kind, Helix, seems to be emerging in San Francisco,
as reported by the MIT Technology Review. This company will collect sputum
samples from customers (patients or healthy individuals), who will buy a DNA
application for their smartphones. The company will then sequence the exomes of
its customers, thereby generating and storing large amounts of genetic information
that it will make available to consumers. The entry price for customers is low, at
about 100 dollars. This company is based on a TSM model, but it is also a ‘‘pay-as-
you-go’’ model (Regalado 2016a). This brings us back to fundamental questions
about the content and form of informed consent, but also to questions about the
ownership of biological samples and genetic data. Genetic data have become a
commodity like any other, at least in North America and some European countries
(UK) (Mullard 2015; Dorfman 2013).
However, the ownership of genetic data is not a straightforward issue. First, from
an economic point of view, these data must be considered ‘‘public goods’’ (Stiglitz
1999), that is, goods that are both non-rival and non-excludable (Leveˆque and
Me´nie`re 2003). They are non-rival goods because they are not exhaustible: the
consumption of public goods by one individual does not prevent another individual
from using or consuming the same public goods. They are non-excludable because
it is difficult to prevent a particular individual from using them. Once disclosed,
genetic data can circulate freely and, in the absence of specific legal provisions, can
be used by all, even those not participating in the sequencing or analysis processes.
As a direct consequence of these characteristics, genetic data are not considered
to be ‘‘scarce’’ and their ownership cannot be justified on an economic basis,
particularly at a time at which the price of sequencing is rapidly decreasing.
On the contrary, it would be appropriate to ensure open access to these data, to
prevent their use for research and care being limited to those controlling them. Even
if these data cannot be appropriated as such, economic actors try to protect them
with legal devices, such as exclusivity agreements, confidentiality agreements or
intellectual property rights (Stiglitz 2007–2008), such as those used to protect
databases in Europe. Such protective arrangements provide the holders of the data
with the power to control downstream markets in care and research (Kitch 1980).
This control raises serious ethical problems if it jeopardizes access to care at a
reasonable cost for all, or favors a move from social insurance systems based on
solidarity to systems based on individual ability to pay.
Other questions are also emerging about the consequences of increases in the
flow of genetic data between patients and industry: will industry always need
academic medical centers for the development and testing of new drugs and tools?
Will patients always need academic medical centers, or even physicians, for
diagnosis and treatment? These questions are clearly relevant to the large numbers
of individuals subscribing to offers of this kind [ 1,000,000 over only 10 years for
23andMe (Stoekle et al. 2016)] and likely to request the new blood test for cancer
being developed by Illumina. Indeed, the company recently said that it will form a
new company (Grail) to develop a blood test, costing $1000 (or less), for detecting
cancers before the onset of symptoms. Illumina predicts that this blood test will
reach the market by 2019 (Regalado 2016b).
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The Pan Cancer Analysis of Whole Genomes project has demonstrated that the use
of cloud computing is much faster and cheaper than the use of conventional academic
data centers for the analysis of large amounts of data. In this context, another approach
to ensuring free access might be to ensure that all major genetic data be uploaded onto
academic and commercial clouds, to prevent private companies, such as GAFA, from
obtaining full control over these data (Stein et al. 2015). This process could be
managed by MTB and e-IC, reducing costs by keeping the patients out of hospital but
staying in real-time communication with them. IT could be used to manage all
communication facilities for the development of cancer research, but it would not be
competent to manage the message. We believe that academic medical centers remain
the best structure for this purpose. This principle seems to have been applied by the
Geisinger Health Institute (US) since 2006 [Geisinger website (www.geisinger.org)].
However, the final decision will probably depend on whether societies choose to
organize their social insurance systems on the basis of solidarity, as in France, or
according to individual ability to pay, as in the United States and many other countries.
Conclusion
In the new era of DM, biobanking, data banking, integration and processing are
becoming essential. It is now clear that clinicians, researchers and industry are
starting to understand the need to use genomics, bioinformatics, biostatistics,
computer algorithms and machine or deep learning to handle the large amounts of
complex genetic data produced and banked effectively for use in care and research
in academic medical centers. However, it remains unclear how and why they should
provide such data to patients. MTB and e-IC are, thus, much more than just simple
structures or forms. They are new ways of organizing the functioning of academic
medical centers for DM, to strengthen ties with patients, clinicians, researchers and
industry, and to prevent private companies from establishing a monopoly for the
storage and analysis of biological samples and genetic data. This issue is of
particular importance in countries in which social insurance systems are based on
solidarity, rather than individual ability to pay. Yesterday’s world belonged to
countries with oil wells and refineries. Tomorrow’s world will belong to those with
biobanks, databases, algorithms and artificial intelligence for the generation of big
data and data mining. We all need to be aware of this, patients above all.
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